Clinical trials: sponsored by Canadian Cancer Trials Group
Early Breast Cancer
Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer
The best available evidence suggests that pregnancy after breast cancer does not increase a woman's risk of developing a recurrence from her breast cancer.
- Trial name
- POSITIVE (NCT02308085)
- Testing
- Endocrine therapy interruption
- Where
- 211 sites in United States, Australia and 20 more
- Volunteers
- 518 people
- Sponsor
- ETOP IBCSG Partners Foundation
Relapsed Non Hodgkin Lymphoma, Relapsed Adult ALL
Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL)
Autologous, unselected CD3+ lymphocytes collected from apheresis, transfected with a lentiviral vector containing a 2nd generation chimeric antigen receptor (CAR) consisting of a scFv recognizing CD19 and dual co-stimulatory…
- Conditions
- Relapsed Non Hodgkin Lymphoma, Relapsed Adult ALL, Relapsed Pediatric ALL
- Trial name
- ACIT001/EXC002 (NCT03938987)
- Testing
- autologous CD19-directed chimeric antigen receptor (CAR) T-cells
- Where
- 6 sites in Canada
- Volunteers
- 63 people
- Sponsor
- University of Alberta
Advanced Cancer
RP-6306 in Patients With Advanced Cancer
This study is being done to answer the following questions: Is the new drug, RP-6306, safe to use, and what effects does it have on cancer when given with standard treatment? If there are specific biomarkers, do patients have an…
- Trial name
- NCT05605509
- Testing
- RP-6306, Gemcitabine, FOLFIRI Protocol
- Where
- 6 sites in Canada
- Volunteers
- 28 people
- Sponsor
- Canadian Cancer Trials Group
Vulvar Cancer
STRatIfication of Vulvar Squamous Cell Carcinoma by HPV and p53 Status to Guide Excision
Vulvar cancer affects the external genitalia of women. This type of cancer is uncommon, arising mostly in older women and has been neglected in research and clinical trials.
- Trial name
- STRIVE (NCT05576831)
- Testing
- Re-excision
- Where
- Canada
- Volunteers
- 249 people
- Sponsor
- British Columbia Cancer Agency
Hodgkin Lymphoma
Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma
This study is being done to determine if two new drugs can shrink or eliminate classical Hodgkins lymphoma.
- Trial name
- NCT05180097
- Testing
- Gemcitabine, Dexamethasone, Cisplatin
- Where
- 18 sites in Australia, Canada
- Volunteers
- 84 people
- Sponsor
- Canadian Cancer Trials Group
Brain and Central Nervous System Tumors
Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma
Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from…
- Trial name
- NCT00887146
- Testing
- concomitant temozolomide (TMZ), radiotherapy, procarbazine
- Where
- 291 sites in United States, Austria and 4 more
- Volunteers
- 305 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Cancer, Covid-19
Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure
The purpose of this study is to find out if immunization with IMM-101 will reduce the incidence of severe respiratory and COVID-19 infections in cancer patients.
- Trial name
- COV-IMMUNO (NCT04442048)
- Testing
- IMM-101, Observation
- Where
- 8 sites in Canada
- Volunteers
- 195 people
- Sponsor
- Canadian Cancer Trials Group
Colon Cancer (High-risk Stage III: pT4N1 or pT1 to 4 N2)
IRinotecan and Oxaliplatin for Colon Cancer in Adjuvant Setting
The trial is a phase III, multicenter, open-labeled randomized trial comparing the association of 5-fluorouracil (5-FU), folinic acid, irinotecan, and oxaliplatin (mFOLFIRINOX) versus oxaliplatin, folinic acid, and 5-FU (mFOLFOX…
- Trial name
- IROCAS (NCT02967289)
- Testing
- Irinotecan, Folfox Protocol
- Where
- 17 sites in Canada, France
- Volunteers
- 792 people
- Sponsor
- UNICANCER
Prostate Cancer
Phase III Radium 223 mCRPC-PEACE III
The primary objective of the trial is to assess if upfront combination of enzalutamide and Ra223 improves radiological progression-free survival (rPFS1) by investigator assessment compared to enzalutamide single agent in…
- Trial name
- PEACE III (NCT02194842)
- Testing
- Ra223, Enzalutamide
- Where
- 64 sites in Belgium, Brazil and 10 more
- Volunteers
- 446 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Prostate Cancer
Prostate Cancer Biomarker Enrichment and Treatment Selection
The purpose of the pre-study screening is to test for DNA abnormalities or biomarkers.
- Trial name
- NCT03385655
- Testing
- Adavosertib, Savolitinib, Darolutamide
- Where
- 11 sites in Canada
- Volunteers
- 200 people
- Sponsor
- Canadian Cancer Trials Group
Newly Diagnosed Glioblastoma
A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma
The standard of care for newly diagnosed glioblastoma includes surgery, involved-field radiotherapy, and concomitant and six cycles of maintenance temozolomide chemotherapy, however the prognosis remains dismal.
- Trial name
- MIRAGE (NCT03345095)
- Testing
- Marizomib, Temozolomide, radiotherapy
- Where
- 82 sites in United States, Austria and 10 more
- Volunteers
- 749 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Recurrent Bladder Urothelial Carcinoma, Stage 0a Bladder Urothelial Carcinoma AJCC v6 and v7
Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer
This phase II trial studies how well atezolizumab works in treating patients with non-muscle invasive bladder cancer that has come back (recurrent) and has not responded to treatment (refractory) with Bacillus Calmette-Guerin…
- Conditions
- Recurrent Bladder Urothelial Carcinoma, Stage 0a Bladder Urothelial Carcinoma AJCC v6 and v7, Stage 0is Bladder Urothelial Carcinoma AJCC v6 and v7, Stage I Bladder Urothelial Carcinoma AJCC v6 and v7
- Trial name
- NCT02844816
- Testing
- Atezolizumab
- Where
- 272 sites in United States, Canada
- Volunteers
- 172 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer
The purpose of this study is to find out the effects of giving durvalumab alone or in combination with tremelimumab on this type of cancer.
- Trial name
- NCT02788773
- Testing
- Durvalumab, Tremelimumab
- Where
- 11 sites in Canada
- Volunteers
- 52 people
- Sponsor
- Canadian Cancer Trials Group
Pancreatic Adenocarcinoma
Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma
The standard or usual treatment for this disease consists of two chemotherapy drugs gemcitabine and nab-paclitaxel given together.
- Trial name
- NCT02879318
- Testing
- Gemcitabine, Nab-paclitaxel, Durvalumab
- Where
- 27 sites in Canada
- Volunteers
- 180 people
- Sponsor
- Canadian Cancer Trials Group
Neoplasms, Breast
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D
This was a four-arm (parallel group) randomized, open-label, multicenter Phase 3 study to investigate the use of a combination of Lapatinib and Trastuzumab, a sequence of Trastuzumab followed by Lapatinib, and Lapatinib alone…
- Trial name
- ALTTO (NCT00490139)
- Testing
- Lapatinib, Trastuzumab
- Where
- 924 sites in United States, Argentina and 42 more
- Volunteers
- 8,381 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Rare Tumours
Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours
The standard or usual treatment for this disease may be chemotherapy or other types of treatment to slow the spread of the disease and relieve some symptoms of this cancer.
- Trial name
- NCT02879162
- Testing
- Durvalumab, Tremelimumab
- Where
- 13 sites in Canada
- Volunteers
- 140 people
- Sponsor
- Canadian Cancer Trials Group
Prostatic Neoplasms
Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer
The purpose of this study is to determine the effectiveness of enzalutamide, versus a conventional non-steroidal anti androgen (NSAA), when combined with a luteinizing hormone releasing hormone analog (LHRHA) or surgical…
- Trial name
- ENZAMET (NCT02446405)
- Testing
- Enzalutamide, NSAA, LHRHA or Surgical Castration
- Where
- 82 sites in United States, Australia and 4 more
- Volunteers
- 1,125 people
- Sponsor
- University of Sydney
Locally Advanced Papillary Renal Cell Carcinoma, Metastatic Papillary Renal Cell Carcinoma
Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed
This phase II trial studies how well cabozantinib s-malate, crizotinib, savolitinib, or sunitinib malate work in treating patients with kidney cancer that has spread from where it started to nearby tissue or lymph nodes or to…
- Conditions
- Locally Advanced Papillary Renal Cell Carcinoma, Metastatic Papillary Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7
- Trial name
- NCT02761057
- Testing
- Biospecimen Collection, Bone Scan, Cabozantinib S-malate
- Where
- 595 sites in United States, Canada
- Volunteers
- 152 people
- Sponsor
- National Cancer Institute (NCI)
Cervical Cancer
Radical Versus Simple Hysterectomy and Pelvic Node Dissection With Low-risk Early Stage Cervical Cancer
The reason this study is being done is to see if a simple hysterectomy is as good as a radical hysterectomy in preventing cancer of the cervix from returning, and whether, because less tissue surrounding the uterus is removed…
- Trial name
- SHAPE (NCT01658930)
- Testing
- Radical Hysterectomy + pelvic lymph node dissection, Simple hysterectomy + pelvic lymph node dissection
- Where
- 87 sites in Austria, Belgium and 9 more
- Volunteers
- 700 people
- Sponsor
- Canadian Cancer Trials Group
Mesothelioma
Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma
Pembrolizumab is a new type of drug for mesothelioma (immunotherapy). Laboratory tests show that this drug works by helping improve the body's immune response to help fight cancer.
- Trial name
- NCT02784171
- Testing
- Cisplatin, Pemetrexed, Pembrolizumab
- Where
- 57 sites in Canada, France and 1 more
- Volunteers
- 520 people
- Sponsor
- Canadian Cancer Trials Group